"治疗没有专用的儿童剂型，孩子不得不服用成人药物。"交汇点新闻客户端"我请代表委员捎句话"栏目 中，不少家长对于部分儿童用药"剂量靠猜、用药靠掰"的现象表达了忧虑。 "儿童用药短缺难题是长期存在的系统性顽疾。"省政协委员，南京医科大学附属儿童医院烧伤整形外科 主任、美容中心主任沈卫民在走访调研多家医疗机构、药企并倾听家长心声后，带来系统性破解我省儿 童用药难题的针对性方案。 沈卫民围绕"强化顶层设计、激发市场活力、完善标准建设、普及科普认知"四个方面提出具体建 议。"建议我省制定儿童药物研发中长期战略，在泰州等医药谷设立专门研发机构，设立专项基金支持 核心技术攻关，优化儿童药注册审批规则，开通临床急需儿童药特别审批通道，给予创新儿童药更长市 场独占期，加速填补用药空白。"他表示，同时要实施"研、产、销"一体化财税金融激励，提高儿童药 研发费用加计扣除比例，将其纳入集中带量采购单独分组，改革定价与医保支付机制，优先将儿童专用 药纳入医保目录，激发企业内生动力。此外，还要引导企业开发适配不同年龄段儿童的友好剂型，完善 儿童药物技术标准，强制推行儿童药"友好包装"与专用量具。 （来源：新华日报） □ 本报记者 孙晟 ...

Core Viewpoint - Yipinhong's stock price has shown a slight increase of 0.18% year-to-date, but has experienced significant declines over various time frames, indicating potential volatility in the stock performance [2]. Group 1: Stock Performance - On February 3, Yipinhong's stock rose by 2.00%, reaching a price of 33.61 CNY per share, with a trading volume of 1.24 billion CNY and a turnover rate of 0.89%, resulting in a total market capitalization of 15.181 billion CNY [1]. - The stock has decreased by 5.03% over the last five trading days, 6.35% over the last 20 days, and 31.24% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Yipinhong reported a revenue of 814 million CNY, reflecting a year-on-year decrease of 34.35%, while the net profit attributable to shareholders was -136 million CNY, showing a year-on-year increase of 44.80% [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million CNY in dividends, with 151 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of January 31, the number of Yipinhong's shareholders reached 30,500, an increase of 14.93% from the previous period, with an average of 13,705 circulating shares per shareholder, a decrease of 12.99% [2]. - Notable new shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and several mutual funds entering the top ten circulating shareholders [3].

Group 1 - The company ST HuLuWa expects a net loss attributable to shareholders of the parent company between -210 million to -310 million yuan for the year 2025, indicating a decline compared to the same period last year [1] - The primary reasons for the performance change include adjustments in industry policies and market environment, leading the company to proactively modify the sales model for certain clients and optimize marketing channel layouts, resulting in decreased product sales and gross margin levels [1] - The completion and capitalization of the Haikou Meian Children's Medicine Intelligent Manufacturing Base and the second phase of the Guangxi Weiwei production base have led to increased fixed asset depreciation expenses, alongside rising bank loan interest expenses and ongoing R&D investments, which have negatively impacted the company's operating performance for the reporting period [1] Group 2 - Despite facing challenges from industry fluctuations, the company has implemented relevant countermeasures, including optimizing customer management, promoting customer tiered management, and enhancing cooperation depth with high-quality clients [1] - The company is also focusing on deepening cost control and improving operational efficiency through refined management practices, strictly controlling expenditure, and striving to enhance operating performance by reducing costs and increasing efficiency [1]

（编辑 王雪儿） 证券日报网讯 1月29日，一品红在互动平台回答投资者提问时表示，公司是一家集药品研发、生产、销 售为一体的创新型生物医药企业，聚焦于儿童药和慢病药领域。公司始终坚持医药创新和高品质药品研 发。除了自主研发创新外，公司还通过合资合作，战略投资等多元开放的方式，布局公司未来可持续发 展创新产品。在儿童药领域，公司坚持以儿童临床需求为导向，采取自主研发与合作开发等模式相结 合，致力于儿童用药的全面技术创新，以提高儿童专用制剂的研发水平，研制口感佳、安全性高、剂量 精准的儿童药物，重点解决儿童用药依从性差、安全隐患多等临床难题。目前，公司着力打造儿童用药 特殊制剂创新研发基地，开发更多适合儿科患者的特殊专用制剂产品。 ...

格隆汇1月29日丨一品红(300723.SZ)在投资者互动平台表示，公司是一家集药品研发、生产、销售为一 体的创新型生物医药企业，聚焦于儿童药和慢病药领域。公司始终坚持医药创新和高品质药品研发。除 了自主研发创新外，公司还通过合资合作，战略投资等多元开放的方式，布局公司未来可持续发展创新 产品。 在儿童药领域，公司坚持以儿童临床需求为导向，采取自主研发与合作开发等模式相结合，致 力于儿童用药的全面技术创新，以提高儿童专用制剂的研发水平，研制口感佳、安全性高、剂量精准的 儿童药物，重点解决儿童用药依从性差、安全隐患多等临床难题。目前，公司着力打造儿童用药特殊制 剂创新研发基地，开发更多适合儿科患者的特殊专用制剂产品。 ...

Group 1 - The stock of Yipinhong Pharmaceutical Group Co., Ltd. fell by 5.22% to 36.83 CNY per share, with a trading volume of 345 million CNY and a turnover rate of 2.18%, resulting in a total market capitalization of 16.636 billion CNY [1] - Yipinhong was established on February 4, 2002, and listed on November 16, 2017. The company is located in Guangzhou, Guangdong Province, and its main business involves the research, production, and sales of proprietary drugs, as well as the sales of agency drugs [1] - The revenue composition of Yipinhong includes 61.12% from pediatric drugs, 22.71% from chronic disease drugs, and 16.17% from other products [1] Group 2 - According to data from the top ten holdings of funds, one fund under Bosera Asset Management holds Yipinhong as a significant investment. The Bosera New Strategy Mixed A Fund (001522) held 17,600 shares in the third quarter, accounting for 1.85% of the fund's net value, ranking as the seventh largest holding [2] - The Bosera New Strategy Mixed A Fund was established on November 23, 2015, with a latest scale of 55.9469 million CNY. Year-to-date returns are 3.44%, ranking 5041 out of 8847 in its category, while the one-year return is 12.24%, ranking 6188 out of 8094 [2] - The fund managers, Li Chongyang and Luo Xiao, have tenures of 2 years and 345 days, and 3 years and 110 days respectively, with total assets under management of 1.106 billion CNY and 18.779 billion CNY respectively [2]

Group 1 - The stock of Yipinhong Pharmaceutical Group Co., Ltd. fell by 5.01% on January 15, closing at 39.66 yuan per share, with a trading volume of 562 million yuan and a turnover rate of 3.32%, resulting in a total market capitalization of 17.914 billion yuan [1] - Yipinhong was established on February 4, 2002, and went public on November 16, 2017. The company is located in Guangzhou, Guangdong Province, and its main business includes the research, production, and sales of proprietary drugs, as well as the sales of agency drugs [1] - The revenue composition of Yipinhong's main business includes 61.12% from pediatric drugs, 22.71% from chronic disease drugs, and 16.17% from other products [1] Group 2 - According to data from the top ten heavy stocks of funds, one fund under Huaxia Fund holds a significant position in Yipinhong. The Huaxia New Jinhui Mixed A Fund (004048) held 23,000 shares in the third quarter, accounting for 2.58% of the fund's net value, making it the sixth-largest heavy stock [2] - The Huaxia New Jinhui Mixed A Fund was established on March 8, 2017, with a latest scale of 14.8028 million. Year-to-date, it has lost 0.49%, ranking 8631 out of 8840 in its category; over the past year, it has gained 13.41%, ranking 6028 out of 8094; and since inception, it has achieved a return of 15.81% [2] - The fund manager of Huaxia New Jinhui Mixed A is Hu Jie, who has been in the position for 2 years and 286 days, with the total asset scale of 52.9889 million yuan. The best fund return during his tenure is 6.22%, while the worst is 5.93% [2]

Group 1 - The core viewpoint of the news is that Yipin Hong's stock has shown volatility with a recent increase in price, but the company faces challenges in revenue and profit margins [1][2]. - As of January 9, Yipin Hong's stock price increased by 2.11% to 36.78 CNY per share, with a total market capitalization of 16.613 billion CNY [1]. - The company has experienced a 9.63% increase in stock price year-to-date, but a significant decline of 33.88% over the past 60 days [1]. Group 2 - For the fiscal year ending December 31, Yipin Hong reported a revenue of 814 million CNY, a decrease of 34.35% year-on-year, while the net profit attributable to shareholders was -136 million CNY, reflecting a growth of 44.80% [2]. - The company has distributed a total of 335 million CNY in dividends since its A-share listing, with 151 million CNY distributed over the past three years [3]. - As of September 30, 2025, Yipin Hong's shareholder count increased by 30.22% to 26,500, while the average circulating shares per person decreased by 23.21% to 15,750 shares [2].

Core Insights - The new policy from the National Medical Products Administration (NMPA) aims to expedite the entry of globally innovative drugs into China, particularly for rare and chronic diseases, by revising the approval timeline for thousands of foreign drugs already on the market [1][2] Group 1: Policy Changes - The NMPA encourages the application of urgently needed foreign drugs, allowing them to be included in the priority review and approval process [1][3] - For rare disease drugs that are urgently needed but not yet available in China, the policy allows for a pre-inspection application process, reducing the registration inspection time from 60 days to 40 days for sample inspections, and from 90 days to 70 days for simultaneous standard review and sample inspection [1][3] - The new policy simplifies previous high inspection requirements, making it easier for rare disease drugs to enter the Chinese market [1][3] Group 2: Industry Impact - The new policy is expected to significantly impact the pharmaceutical industry by accelerating the market entry of urgently needed drugs, particularly for rare diseases, thus addressing the issue of drug accessibility for patients [2][5] - The introduction of a mechanism for foreign generic drug applications is anticipated to provide more economical treatment options alongside original drugs, potentially reducing the financial burden on patients [2][5] - The policy encourages pharmaceutical companies to conduct global synchronized research and applications in China, which may lead to better resource allocation and earlier inclusion of China in global research plans [2][5] Group 3: Regulatory Framework - The policy establishes a communication channel for applicants to discuss data utilization and priority review with the drug review center before formal application submission, which is crucial for expediting the process [3][4] - It allows for the acceptance of foreign clinical data and conditional approvals, which can significantly shorten the time to market and reduce costs [3][4] - The policy also optimizes the risk management mechanism for foreign reviews, allowing for remote inspections, which eases the burden on companies while raising quality control standards [4][5] Group 4: Market Dynamics - The global pharmaceutical industry is projected to face a "patent cliff" of approximately $236 billion from 2025 to 2030, prompting multinational companies to adjust their strategies in China [6][7] - The new policy shifts the focus from a "low-price only" approach to a comprehensive evaluation of clinical value, creating conditions for multinational companies to receive reasonable returns on their products [6][7] - The market for rare disease drugs is expected to become a new growth area, with the policy lowering barriers for these drugs to enter the Chinese market [6][7] Group 5: Future Considerations - The implementation of the new policy may face challenges, including the need for complementary measures, particularly regarding insurance integration [7][8] - The regulatory capacity of relevant agencies will be tested as the new policy significantly compresses review timelines, requiring enhanced human resource allocation and professional capabilities [8][9] - The pharmaceutical sector is expected to see a strong rebound in 2025, driven by AI and innovative drugs, reflecting a qualitative leap in China's innovation capabilities [10][11]

Core Insights - China is enhancing support for innovative drugs with new mechanisms and targets throughout the entire process from communication, clinical trials, registration, to review and approval, aiming to facilitate "China's first launch" of innovative drugs [1][2] Group 1: Regulatory Developments - The National Medical Products Administration (NMPA) approved a record 4,087 drug registration applications in 2022, including 76 innovative drugs, marking a historical high [2] - The time gap for domestic and international drug listings has been further reduced, with 59 foreign new drugs receiving temporary import approval [2] - A priority review and approval mechanism for pediatric drugs has been continuously promoted, resulting in the approval of 138 pediatric drugs in 2022 [2] Group 2: Focus on Rare Diseases - The temporary import channel for rare disease drugs remains open, with 48 rare disease drugs approved in 2022, effectively filling the medication gap for special populations [2] Group 3: Internationalization of the Pharmaceutical Industry - The internationalization of the pharmaceutical industry is accelerating, with cumulative overseas licensing transactions for innovative drugs exceeding $130 billion, indicating China's transition towards becoming a major exporter of innovative drugs [2] Group 4: Future Initiatives - In 2026, the NMPA plans to implement targeted measures, including the establishment of a drug trial data protection system and a market exclusivity system for pediatric and rare disease drugs [2] - The NMPA will strengthen service support for new mechanism and target innovative drugs across the entire chain, and pilot pre-application services for new generic drugs in selected regions to enhance application quality [2]